Type 2 diabetes: As Semaglutide goes off patent, drugmakers compete on differentiation, not just price
With multiple launches lined up for March, companies are betting on device innovation, brand strategy, and patient-support ecosystems to capture share in India’s expanding metabolic care market.
With multiple launches lined up for March, companies are betting on device innovation, brand strategy, and patient-support ecosystems to capture share in India’s expanding metabolic care market.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
